alexa Stat3-Syk Molecular Complex as A Target for Anti-Cancer Nanomedicines | OMICS International
ISSN: 2157-7439
Journal of Nanomedicine & Nanotechnology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Stat3-Syk Molecular Complex as A Target for Anti-Cancer Nanomedicines

Fatih M Uckun1,2,3*

1Keck Medical Center of University of Southern California, Los Angeles, CA

2Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA

3The Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, CA

*Corresponding Author:
Fatih Uckun
Professor, Department of Pediatrics
Keck School of Medicine
University of Southern California
Los Angeles, CA
E-mail: [email protected]

Received Date: June 25, 2012; Accepted Date: June 25, 2012; Published Date: June 27, 2012

Citation: Uckun FM (2012) Stat3-Syk Molecular Complex as A Target for Anti- Cancer Nanomedicines. J Nanomed Nanotechol 3:e110. doi:10.4172/2157-7439.1000e110

Copyright: © 2012 Uckun FM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Nanomedicine & Nanotechnology

Spleen Tyrosine Kinase (SYK) can activate the oncogenic transcription factor “The Signal Transducer and Activator of Transcription 3” (STAT3) to induce expression of STAT3 target genes that protect cancer cells against chemotherapy and ionizing radiation [1]. A meta-analysis using the Oncomine database revealed a marked enrichment of the most discriminating SYK-dependent anti-apoptotic genes in human leukemias and lymphomas [2]. In patients that showed upregulation of SYK, the majority of comparisons also showed significant upregulation of the STAT3 target genes. SYK has also been shown to regulate the activation of the mammalian target of rapamycin (mTOR), an evolutionarily conserved serine/threonine kinase that is controlled by the SYK-regulated PI3-K/AKT and MAPK/ERK pathways [2,3]. Notably, the anti-apoptotic NFkB is also regulated by SYK [2]. Thus, STAT3-SYK molecular complex is a master regulator of apoptosis and neoplastic expansion in leukemias and lymphomas [2]. Several structurally distinct and highly potent small molecule inhibitors of SYK tyrosine kinase ATP binding site have been developed [4-7]. In addition to small molecule tyrosine kinase inhibitors, antisense oligonucleotides and small interfering RNAs (siRNAs) have also been developed to knock down SYK expression [8,9].

We recently discovered the pentapeptide mimic 1,4-Bis (9-O dihydroquinidinyl) phthalazine / hydroquinidine 1,4-phathalazinediyl diether (C-61) as a tyrosine kinase inhibitor targeting the substrate binding P-site of SYK and as a novel drug candidate against B-lineage leukemias and lymphomas [1,4,5]. C-61 inhibits SYK in both cellfree and cellular kinase assays at nanomolar concentrations, acts as a potent inducer of apoptosis in chemotherapy-resistant primary leukemic B-cell precursors taken directly from relapsed B-lineage ALL patients, exhibits favorable pharmacokinetics in mice and nonhuman primates, and eradicates leukemia-initiating cells in SCID mouse xenograft models of chemotherapy-resistant human B-lineage ALL at dose levels non-toxic to mice and non-human primates [1,4,5]. C-61 prevented radiation-induced activation of SYK and markedly augmented radiation-induced apoptosis of leukemia/lymphoma cells and enhanced the anti-leukemic potency of total body irradiation (TBI) in the context of hematopoietic stem cell transplantation (SCT) [5]. Based on this preclinical proof-of-principle study, we hypothesize that the incorporation of C-61 into the pre-transplant TBI regimens of patients with recurrent or high risk leukemias/lymphomas will help overcome the radiochemotherapy resistance of their cancer cells and thereby improve their treatment response and survival outcome after hematopoietic SCT.

The efficient delivery of the various SYK inhibitors by leveraging nanotechnology holds particular promise. Liposomal nanoparticle therapeutics containing active anti-cancer agents, including targetspecific small molecules and siRNA, may provide the foundation for potentially more effective and less toxic anti-cancer treatment strategies due to their improved pharmacokinetics, reduced systemic toxicity, and increased intra-tumoral/intra-cellular delivery [10-14]. Nanoparticles have been coated with Polyethylene Glycol (PEG) in an attempt to render them resistant against protein adsorption, enhance their biocompatibility, and to stabilize them against agglomeration in biological environments. PEGylated nanoparticles with diameters around 100-nm may become long-circulating in the blood stream and have been called stealth particles since they can evade recognition by T-cells and macrophages and avoid rapid clearance by the immune system [10-14]. Nanoparticles that are sterically stabilized by PEG polymers on their surface and have surface charges that are slightly negative or slightly positive have minimal self-self or self-nonself interactions and improved pharmacokinetics. PEGylation of nanoparticles creates a hydrophilic surface and leads to increased protein solubility, reduced immunogenicity, prolonged plasma half-life due to prevention of rapid renal clearance, and reduced clearance by the RES system due to decreased macrophage capture and opsonization [10-14]. The rationally engineered nanoparticle constructs of SYK inhibitors are likely to be less toxic and more effective than free molecules.

Nanoparticles can be functionalized with a tumor targeting moiety such as a ligand or (Single chain variable fragment) scFv directed against a surface receptor on cancer cells in order to achieve optimal tumor targeting and site-specific drug delivery to further reduce their toxicity and improve their efficacy [10-14]. When linked with tumor targeting moieties nanoparticles can reach cancer cells carrying the target receptors with high affinity and precision. The targeting ligands enable nanoparticles to bind to cell surface receptors and enter cells by receptor-mediated endocytosis. In our own program, efforts are underway to prepare nanoparticles targeted against the CD19 antigen on childhood leukemia cells. Likewise, we are preparing nanoparticles functionalized with recombinant human Insulin-Like Growth Factor 1 (IGF1) to target surface IGF1 receptors on solid tumor cells. Rationally engineered nanoparticle therapeutics containing C-61 may provide the foundation for potentially more effective and less toxic anti-cancer treatment strategies due to their improved pharmacokinetics, reduced systemic toxicity, and increased intra-tumoral/intra-cellular delivery [5]. We hypothesize that the nanotechnology-enabled delivery of C-61 [14] will be associated with reduced toxicity enhanced potency compared to the free drug delivery with the salt-formulation used in our recent preclinical studies. Further development of rationally designed SYK inhibitors and their nanoscale formulations may provide the foundation for therapeutic innovation against a broad spectrum of cancers, especially leukemias and lymphomas.

Acknowledgements

F.M.U is supported by DHHS/NIH grants U01-CA-151837, R01-CA-154471, Couples against Leukemia Foundation and a V Foundation Translational Research Grant.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 11593
  • [From(publication date):
    July-2012 - Dec 16, 2017]
  • Breakdown by view type
  • HTML page views : 7825
  • PDF downloads : 3768
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]m

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version